文献速递头颈与中枢神经肿瘤

吉西他滨联合顺铂诱导化疗治疗鼻咽癌的最终总生存分析:多中心随机III期试验

Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
PubMed 文献 · J Clin Oncol · 2022-06-16

多中心随机III期试验最终总生存分析显示,局部晚期鼻咽癌患者接受吉西他滨联合顺铂诱导化疗后同步放化疗,中位随访69.8个月,5年总生存率87.9%对78.8%,风险比0.51,晚期毒性风险相当。诱导化疗肿瘤缓解深度与生存正相关,治疗前血浆游离EB病毒DNA载量低(<4000拷贝/mL)的患者可能未获益。

要点

  • 诱导化疗组5年总生存率87.9%,标准治疗组78.8%,风险比0.51(95%CI 0.34~0.78),P=0.001。
  • 两组≥3级晚期毒性发生率分别为11.3%和11.4%,风险相当。
  • 诱导化疗后完全缓解、部分缓解、稳定/进展患者5年总生存率分别为100%、88.4%、61.5%,P=0.005。

核心结论

  • 局部晚期鼻咽癌患者同步放化疗前接受吉西他滨联合顺铂诱导化疗可显著改善总生存,且不增加晚期毒性风险。
  • 诱导化疗的肿瘤缓解深度及治疗前血浆游离EB病毒DNA载量可能有助于指导个体化治疗。

研究设计与样本

  • 多中心随机III期试验,患者随机接受单纯同步放化疗(标准治疗,n=238)或吉西他滨联合顺铂诱导化疗后同步放化疗(n=242)。
  • 中位随访69.8个月,本次报告最终总生存分析。

主要发现

  • 诱导化疗组5年总生存率87.9%,标准治疗组78.8%,风险比0.51(95%CI 0.34~0.78),P=0.001。
  • 两组≥3级晚期毒性发生率分别为11.3%和11.4%,风险相当。
  • 诱导化疗后完全缓解、部分缓解、稳定/进展患者5年总生存率分别为100%、88.4%、61.5%,P=0.005。
  • 治疗前血浆游离EB病毒DNA载量<4000拷贝/mL的患者,诱导化疗组与标准治疗组5年总生存率分别为90.6%和91.4%,P=0.77,可能未从诱导化疗中获益。

临床怎么用

  • 局部晚期鼻咽癌患者可在同步放化疗前接受吉西他滨联合顺铂诱导化疗以改善总生存。
  • 诱导化疗的肿瘤缓解深度及治疗前血浆游离EB病毒DNA载量可能有助于指导个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We previously reported significantly improved failure-free survival using gemcitabine plus cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Here, we present the final overall survival (OS) analysis. In this multicenter, randomized trial, patients were assigned to be treated with concurrent chemoradiotherapy alone (standard therapy, n = 238) or gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy (n = 242). With a median follow-up of 69.8 months, the induction chemotherapy group had a significantly higher 5-year OS (87.9% v 78.8%, hazard ratio, 0.51 [95% CI 0.34 to 0.78]; P = .001) and a comparable risk of late toxicities (≥ grade 3, 11.3% v 11.4%). Notably, the depth of the tumor response to induction chemotherapy correlated significantly and positively with survival (complete response v partial response v stable/progressive disease, 5-year OS, 100% v 88.4% v 61.5%, P = .005). Besides, patients with a low pretreatment cell-free Epstein-Barr virus DNA load (< 4,000 copies/mL) might not benefit from induction chemotherapy (5-year OS, 90.6% v 91.4%, P = .77). In conclusion, induction chemotherapy before concurrent chemoradiotherapy improved OS significantly in patients with locally advanced nasopharyngeal carcinoma, without increasing the risk of late toxicities. Tumor response to induction chemotherapy and pretreatment cell-free Epstein-Barr virus DNA might be useful to guide individualized treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Chen L, Hu GQ, et al. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2022. PMID: 35709465. doi:10.1200/JCO.22.00327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。